Inclusion Criteria:

- Patient must have histologically confirmed Stage I-IIIA non-small cell lung cancer
(NSCLC) which is accessible to biopsy.

- ECOG Performance Status of 0, 1, or 2.

- Life-expectancy greater than 6 months.

- Adequate bone marrow, renal, hepatic, pulmonary and cardiac function as defined in
the protocol.

- Patient must be at least 18 years of age.

- Must meet pre-entry requirements for timing of study parameters as specified in
section 7.0.

- Female patients of child-bearing potential must have a negative serum pregnancy test
within 48 hours of study initiation and be non-lactating.

- Patients of child-bearing potential must agree to use an effective form of
contraception while on study and for 3 months following completion of study
treatment.

- The use of G-CSF will be permitted in study participants.

- Final eligibility for a clinical trial is determined by the health professionals
conducting the trial.

Exclusion Criteria:

- Patient has received previous treatment for NSCLC.

- Known hypersensitivity to everolimus, sirolimus, or any of its excipients.

- Patient is pregnant or breast-feeding.

- Patient has incurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Patient is unable to swallow RAD001 tablet.

- History of other invasive malignancies, with the exception of non-melanoma skin
cancer, are excluded if there is any evidence of the malignancy being present within
the past five years.

- History of severe hypersensitivity reaction to docetaxel or other drugs formulated
with polysorbate 80. Symptoms may include any reaction such as bronchospasm,
generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema.

- Final eligibility for a clinical trial is determined by the health professionals
conducting the trial.